These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 19238210)
41. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Sos ML; Koker M; Weir BA; Heynck S; Rabinovsky R; Zander T; Seeger JM; Weiss J; Fischer F; Frommolt P; Michel K; Peifer M; Mermel C; Girard L; Peyton M; Gazdar AF; Minna JD; Garraway LA; Kashkar H; Pao W; Meyerson M; Thomas RK Cancer Res; 2009 Apr; 69(8):3256-61. PubMed ID: 19351834 [TBL] [Abstract][Full Text] [Related]
42. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Drilon A; Wang L; Hasanovic A; Suehara Y; Lipson D; Stephens P; Ross J; Miller V; Ginsberg M; Zakowski MF; Kris MG; Ladanyi M; Rizvi N Cancer Discov; 2013 Jun; 3(6):630-5. PubMed ID: 23533264 [TBL] [Abstract][Full Text] [Related]
43. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105 [TBL] [Abstract][Full Text] [Related]
44. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810 [TBL] [Abstract][Full Text] [Related]
46. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. Sequist LV; Besse B; Lynch TJ; Miller VA; Wong KK; Gitlitz B; Eaton K; Zacharchuk C; Freyman A; Powell C; Ananthakrishnan R; Quinn S; Soria JC J Clin Oncol; 2010 Jun; 28(18):3076-83. PubMed ID: 20479403 [TBL] [Abstract][Full Text] [Related]
47. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455 [TBL] [Abstract][Full Text] [Related]
48. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589 [TBL] [Abstract][Full Text] [Related]
49. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459 [TBL] [Abstract][Full Text] [Related]
50. The PI3K pathway as drug target in human cancer. Courtney KD; Corcoran RB; Engelman JA J Clin Oncol; 2010 Feb; 28(6):1075-83. PubMed ID: 20085938 [TBL] [Abstract][Full Text] [Related]
52. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300 [TBL] [Abstract][Full Text] [Related]
53. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087 [TBL] [Abstract][Full Text] [Related]
54. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157 [TBL] [Abstract][Full Text] [Related]
55. Crizotinib in ROS1-rearranged non-small-cell lung cancer. Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305 [TBL] [Abstract][Full Text] [Related]
56. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003 [TBL] [Abstract][Full Text] [Related]
57. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338 [TBL] [Abstract][Full Text] [Related]
58. ROS1 rearrangements define a unique molecular class of lung cancers. Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748 [TBL] [Abstract][Full Text] [Related]
59. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. He M; Capelletti M; Nafa K; Yun CH; Arcila ME; Miller VA; Ginsberg MS; Zhao B; Kris MG; Eck MJ; Jänne PA; Ladanyi M; Oxnard GR Clin Cancer Res; 2012 Mar; 18(6):1790-7. PubMed ID: 22190593 [TBL] [Abstract][Full Text] [Related]
60. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]